Biogen, Elan views on Tysabri's future reflect investments at stake

06/15/2005 | Boston Globe (tiered subscription model), The

Biogen Idec and Elan, partners in developing the now-withdrawn Tysabri multiple sclerosis drug, have different takes on the immediate future of their drug. Kelly Martin, Elan's CEO, predicts Tysabri will be back on the market, but Biogen CEO James Mullen declines to speculate because he does not have the facts yet. The different responses may reflect the investment each firm has in Tysabri.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC